Literature DB >> 23836174

IMP-43 and IMP-44 metallo-β-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa.

Tatsuya Tada1, Tohru Miyoshi-Akiyama, Kayo Shimada, Masahiro Shimojima, Teruo Kirikae.   

Abstract

Two novel IMP-type metallo-β-lactamase variants, IMP-43 and IMP-44, were identified in multidrug-resistant Pseudomonas aeruginosa isolates obtained in medical settings in Japan. Analysis of their predicted amino acid sequences revealed that IMP-43 had an amino acid substitution (Val67Phe) compared with IMP-7 and that IMP-44 had two substitutions (Val67Phe and Phe87Ser) compared with IMP-11. The amino acid residue at position 67 is located at the end of a loop close to the active site, consisting of residues 60 to 66 in IMP-1, and the amino acid residue at position 87 forms a hydrophobic patch close to the active site with other amino acids. An Escherichia coli strain expressing blaIMP-43 was more resistant to doripenem and meropenem but not to imipenem than one expressing blaIMP-7. An E. coli strain expressing blaIMP-44 was more resistant to doripenem, imipenem and meropenem than one expressing blaIMP-11. IMP-43 had more efficient catalytic activities against all three carbapenems than IMP-7, indicating that the Val67Phe substitution contributed to increased catalytic activities against carbapenems. IMP-44 had more efficient catalytic activities against all carbapenems tested than IMP-11, as well as increased activities compared with IMP-43, indicating that both the Val67Phe and Phe87Ser substitutions contributed to increased catalytic activities against carbapenems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836174      PMCID: PMC3754296          DOI: 10.1128/AAC.00716-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Analysis of the importance of the metallo-beta-lactamase active site loop in substrate binding and catalysis.

Authors:  Catherine Moali; Christine Anne; Josette Lamotte-Brasseur; Sylvie Groslambert; Bart Devreese; Jozef Van Beeumen; Moreno Galleni; Jean Marie Frère
Journal:  Chem Biol       Date:  2003-04

2.  Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.

Authors:  Catherine Llanes; Didier Hocquet; Christelle Vogne; Dounia Benali-Baitich; Catherine Neuwirth; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase.

Authors:  Mariana Castanheira; Mark A Toleman; Ronald N Jones; Franz J Schmidt; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Substrate binding and catalytic mechanism of class B beta-lactamases: a molecular modelling study.

Authors:  C Prosperi-Meys; J Wouters; M Galleni; J Lamotte-Brasseur
Journal:  Cell Mol Life Sci       Date:  2001-12       Impact factor: 9.261

5.  Overexpression, purification, and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia.

Authors:  M W Crowder; T R Walsh; L Banovic; M Pettit; J Spencer
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate.

Authors:  L Lauretti; M L Riccio; A Mazzariol; G Cornaglia; G Amicosante; R Fontana; G M Rossolini
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

7.  DIM-1, a novel immunoglobulin superfamily protein in Caenorhabditis elegans, is necessary for maintaining bodywall muscle integrity.

Authors:  Teresa M Rogalski; Mary M Gilbert; Danelle Devenport; Kenneth R Norman; Donald G Moerman
Journal:  Genetics       Date:  2003-03       Impact factor: 4.562

8.  Carbapenem-resistant Pseudomonas aeruginosa in malaysia producing IMP-7 beta-lactamase.

Authors:  Siaw Eng Ho; Geetha Subramaniam; Selvi Palasubramaniam; Parasakthi Navaratnam
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 9.  Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions.

Authors:  Herbert P Schweizer
Journal:  Genet Mol Res       Date:  2003-03-31

10.  Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.

Authors:  E Osano; Y Arakawa; R Wacharotayankun; M Ohta; T Horii; H Ito; F Yoshimura; N Kato
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more
  13 in total

1.  Molecular Characterization of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Hospitals in Myanmar.

Authors:  Tatsuya Tada; Tomomi Hishinuma; Shin Watanabe; Hiroki Uchida; Mari Tohya; Kyoko Kuwahara-Arai; San Mya; Khin Nyein Zan; Teruo Kirikae; Htay Htay Tin
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  A Modified Carbapenem Inactivation Method, CIMTris, for Carbapenemase Production in Acinetobacter and Pseudomonas Species.

Authors:  Kohei Uechi; Tatsuya Tada; Kayo Shimada; Kyoko Kuwahara-Arai; Momoko Arakaki; Takaaki Tome; Isamu Nakasone; Shiro Maeda; Teruo Kirikae; Jiro Fujita
Journal:  J Clin Microbiol       Date:  2017-09-27       Impact factor: 5.948

3.  Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China.

Authors:  Y Chen; M Sun; M Wang; Y Lu; Z Yan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-06       Impact factor: 3.267

4.  Multidrug-Resistant Sequence Type 235 Pseudomonas aeruginosa Clinical Isolates Producing IMP-26 with Increased Carbapenem-Hydrolyzing Activities in Vietnam.

Authors:  Tatsuya Tada; Pham Hong Nhung; Tohru Miyoshi-Akiyama; Kayo Shimada; Mitsuhiro Tsuchiya; Doan Mai Phuong; Nguyen Quoc Anh; Norio Ohmagari; Teruo Kirikae
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Suppression of β-Lactam Resistance by Aspergillomarasmine A Is Influenced by both the Metallo-β-Lactamase Target and the Antibiotic Partner.

Authors:  Caitlyn M Rotondo; David Sychantha; Kalinka Koteva; Gerard D Wright
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  Characterization and distribution of drug resistance associated β-lactamase, membrane porin and efflux pump genes in MDR A. baumannii isolated from Zhenjiang, China.

Authors:  Huijian Yang; Lan Huang; Prince Amoah Barnie; Zhaoliang Su; Zuhuang Mi; Jianguo Chen; Vasudevan Aparna; Dinesh Kumar; Huaxi Xu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 7.  B1-Metallo-β-Lactamases: Where Do We Stand?

Authors:  Maria F Mojica; Robert A Bonomo; Walter Fast
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

8.  Elucidating the Role of Residue 67 in IMP-Type Metallo-β-Lactamase Evolution.

Authors:  Alecander E LaCuran; Kevin M Pegg; Eleanor M Liu; Christopher R Bethel; Ni Ai; William J Welsh; Robert A Bonomo; Peter Oelschlaeger
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

9.  Emergence of Carbapenem-Resistant Providencia rettgeri and Providencia stuartii Producing IMP-Type Metallo-β-Lactamase in Japan.

Authors:  Shu Iwata; Tatsuya Tada; Tomomi Hishinuma; Mari Tohya; Satoshi Oshiro; Kyoko Kuwahara-Arai; Miho Ogawa; Masahiro Shimojima; Teruo Kirikae
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  First Complete Genome Sequence of Pseudomonas aeruginosa (Schroeter 1872) Migula 1900 (DSM 50071T), Determined Using PacBio Single-Molecule Real-Time Technology.

Authors:  Kazuma Nakano; Yasunobu Terabayashi; Akino Shiroma; Makiko Shimoji; Hinako Tamotsu; Noriko Ashimine; Shun Ohki; Misuzu Shinzato; Kuniko Teruya; Kazuhito Satou; Takashi Hirano
Journal:  Genome Announc       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.